Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23782042 | 1.00 | NFKB1 (0.43) | NFKB1NFKB2RELA | |
| SCHEMBL14838051 | 1.00 | NFKB1 (0.43) | NFKB1NFKB2RELA | |
| SCHEMBL4954867 | 1.00 | NFKB1 (0.43) | NFKB1NFKB2RELA | |
| SCHEMBL19606034 | 0.93 | NFKB1 (0.41) | NFKB1NFKB2RELA | |
| SCHEMBL24584247 | 0.93 | NFKB1 (0.41) | NFKB1NFKB2RELA | |
| SCHEMBL24754820 | 0.93 | NFKB1 (0.41) | NFKB1NFKB2RELA | |
| SCHEMBL24963813 | 0.93 | NFKB1 (0.41) | NFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL30800270 | 0.92 | — | — | |
| SCHEMBL23824564 | 0.92 | CTSL (0.51) | — | |
| SCHEMBL23824275 | 0.92 | CTSL (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024222830-A1 | SULFUR-CONTAINING PEPTIDOMIMETIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中国人民解放军军事科学院军事医学研究院 | 2024-10-31 | — | — | WO | claimed |
| CN-114605301-A | Method for preparing intermediate of palovir | 江苏恒沛药物科技有限公司 | 2022-06-10 | — | — | CN | claimed |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | TOCRIS COOKSON LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | TRAWSFYNYDD THERAPEUTICS INC (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4635972-A2 | FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4051265-B1 | FUNCTIONALIZED PEPTIDES CONTAINING TWO PYRROLIDINE RINGS AS ANTICORONAVIRUS AGENTS | ENANTA PHARM INC (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4598914-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | Tocris Cookson Limited (GB) | 2025-08-13 | — | — | EP | disclosed |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| WO-2025133078-A1 | VIRAL PROTEASE INHIBITORS WITH A HYDROXYBENZYL ALCOHOL WARHEAD | STICHTING RADBOUD UNIVERSITEIT (NL) | 2025-06-26 | — | — | WO | disclosed |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2017197377-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
| US-7462594-B2 | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-09 | — | — | US | disclosed |
| US-7462594-B2 | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-09 | — | — | US | disclosed |
| US-20080125375-A1 | PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-05-29 | — | — | US | disclosed |
| US-20080125375-A1 | PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-05-29 | — | — | US | disclosed |
| US-7304088-B2 | Peptide like compounds for treating coronavirus or hepatitis C virus; severe acute respiratory distress syndrome | TAIGEN BIOTECHNOLOGY (TW) | 2007-12-04 | — | — | US | disclosed |
| WO-2005113580-A1 | ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES AND MATERIALS FOR THEIR SYNTHESIS | PFIZER INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050143320-A1 | Protease inhibitors | TAIGEN BIOTECHNOLOGY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376464-A1 | Compounds for treatment a coronavirus infection | ACE2, ACE, TMPRSS2 | NFKB1 3277/4885NFKB2 3362/4885RELA 3202/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | NFKB1 2618/4885NFKB2 3505/4885RELA 4568/4885 |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | NFKB1 168/4885NFKB2 273/4885RELA 257/4885 |
| US-20050143320-A1 | Protease inhibitors | PREP, SPINT2, SERPINB1 | NFKB1 2382/4885NFKB2 2721/4885RELA 2459/4885 |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | NFKB1 2308/4885NFKB2 2990/4885RELA 2513/4885 |
| US-20260137677-A1 | PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 | XIAP, MDM2, SARS1 | NFKB1 1789/4885NFKB2 1528/4885RELA 2624/4885 |
| US-20080125375-A1 | PROTEASE INHIBITORS | PREP, SERPINB1, SPINT2 | NFKB1 2165/4885NFKB2 3054/4885RELA 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.